Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

Summary

To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).

Timeline

Start

2016-06-30

Primary completion

2016-12-07

Completion

2016-12-07

Drugs

Indications